Your browser doesn't support javascript.
loading
Balloon Dilation of the Eustachian Tube: 12-Month Follow-up of the Randomized Controlled Trial Treatment Group.
Anand, Vijay; Poe, Dennis; Dean, Marc; Roberts, William; Stolovitzky, Pablo; Hoffmann, Karen; Nachlas, Nathan; Light, Joshua; Widick, Mark; Sugrue, John; Elliott, C Layton; Rosenberg, Seth; Guillory, Paul; Brown, Neil; Syms, Charles; Hilton, Christopher; McElveen, John; Singh, Ameet; Weiss, Raymond; Arriaga, Moises; Leopold, John.
Afiliação
  • Anand V; 1 Weill Cornell Medical College, New York, New York, USA.
  • Poe D; 2 Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Dean M; 3 Texas Healthcare, PLLC, Fort Worth, Texas, USA.
  • Roberts W; 4 Charlotte Eye, Ear, Nose & Throat Associates, South Park Location, Charlotte, North Carolina, USA.
  • Stolovitzky P; 5 ENT of Georgia, Atlanta, Georgia, USA.
  • Hoffmann K; 6 Piedmont Ear, Nose & Throat & Related Allergy, Atlanta, Georgia, USA.
  • Nachlas N; 7 ENT of South Florida, Boca Raton, Florida, USA.
  • Light J; 8 ENT of South Florida, Boynton Beach, Florida, USA.
  • Widick M; 7 ENT of South Florida, Boca Raton, Florida, USA.
  • Sugrue J; 9 ENT & Allergy Associates, LLP, Port Jefferson, New York, USA.
  • Elliott CL; 10 Witham Health Services/Memorial Hospital, Lebanon, Indiana, USA.
  • Rosenberg S; 11 Florida Ear & Sinus Center, Sarasota, Florida, USA.
  • Guillory P; 12 Red River ENT Associates, Alexandria, Louisiana, USA.
  • Brown N; 13 Meriter-UnityPoint Health, Monona Clinic, Monona, Wisconsin, USA.
  • Syms C; 14 Ear Medical Group, San Antonio, Texas, USA.
  • Hilton C; 15 HealthPartners Medical Group, St Paul, Minnesota, USA.
  • McElveen J; 16 Carolina Ear and Hearing Clinic, Raleigh, North Carolina, USA.
  • Singh A; 17 Division of Otolaryngology, George Washington Medical Faculty Associates, Washington, DC, USA.
  • Weiss R; 18 The Sinus Center of the South, Ocean Springs, Mississippi, USA.
  • Arriaga M; 19 Hearing and Balance Center, Our Lady of the Lake Regional Medical Center; Division of Otology/Neurotology, Department of Otolaryngology, Louisiana State University, Baton Rouge, Louisiana, USA.
  • Leopold J; 20 Depuy Synthes, JNJ Medical Devices, Raynham, Massachusetts, USA.
Otolaryngol Head Neck Surg ; 160(4): 687-694, 2019 04.
Article em En | MEDLINE | ID: mdl-30620688
OBJECTIVE: Obstructive eustachian tube dysfunction (OETD) affects up to 5% of adults; however, available treatment strategies have limitations. It was previously reported that balloon dilation of the eustachian tube (BDET) with the eustachian tube balloon catheter + medical management (MM) results in a significantly higher proportion of subjects with normalized tympanograms versus MM alone at 6- and 24-week follow-up. The current analysis extends these initial findings by investigating the durability of BDET + MM treatment outcomes through 52 weeks. STUDY DESIGN: Prospective cohort follow-up study from the treatment group in a previously reported multicenter randomized controlled trial. SETTING: Twenty-one investigational sites across the United States. SUBJECTS AND METHODS: Here we report on secondary and exploratory endpoints for patients with OETD who previously failed MM and were randomized to the BDET + MM cohort. Analyses of tympanogram outcomes are reported by ear, unless specified otherwise, as a more accurate measure of durability of the procedure over time. RESULTS: Among subjects randomized to BDET + MM, the overall number with normalized tympanograms and ETDQ-7 scores (Eustachian Tube Dysfunction Questionnaire-7) remained comparable to those reported at 6- versus 52-week follow-up: tympanograms, 73 of 143 (51.0%) versus 71 of 128 (55.5%); ETDQ-7, 79 of 142 (55.6%) versus 71 of 124 (57.3%). The overall number of ears with normalized tympanograms also remained comparable, with 117 of 204 (57%) versus 119 of 187 (63.6%). CONCLUSIONS: The present study suggests that the beneficial effects of BDET + MM on tympanogram normalization and symptoms of subjects with refractory OETD demonstrate significant durability that is clinically relevant through 52 weeks.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article